New method for creating inducible stem cells is remarkably efficient

Some of the most challenging obstacles limiting the reprogramming of mature human cells into stem cells may not seem quite as daunting in the near future. Two independent research papers, published by Cell Press in the September 11th issue of the journal Cell Stem Cell, describe new tools that provide invaluable platforms for elucidating the molecular, genetic, and biochemical mechanisms associated with reprogramming. The new findings also offer considerable hope toward making the reprogramming process more therapeutically relevant.

Although scientists have successfully reprogrammed mature human skin cells into induced pluripotent stem (iPS) cells by expressing a few key transcription factors, the conversion has been extremely inefficient. "Little is known about the mechanisms by which reprogramming occurs, in part because of the low efficiency," says senior study author Dr. Konrad Hochedlinger from the Harvard Stem Cell Institute. In addition, the iPS cells created thus far have been generated with retroviruses and noninducible lentiviruses, both of which have major limitations that are not compatible with clinical applications.

The Hochedlinger group created a drug-inducible viral system to generate human iPS cells that were molecularly and functionally similar to human embryonic stem cells. This method was unique in that it allowed the researchers to create iPS cells by using the drug doxycycline to control expression of the necessary factors that had been delivered to the cells with viruses.

The researchers then found that when doxycycline was removed and these "primary" iPS cells differentiated to mature cells, another exposure to the drug reactivated the genes required for reprogramming and induced generation of "secondary" iPS cells at a frequency that was far greater that the initial "primary" conversion. The idea of generating these secondary cells was conceived in previous experiments with mice performed in the lab of Dr. Rudolf Jaenisch from the Massachusetts Institute of Technology.

"The secondary system will enable chemical and genetic screening efforts to identify key molecular constituents of reprogramming, as well as important obstacles in this process, and will ultimately lend itself as a powerful tool in the development and optimization methods to produce human iPS cells," explains Dr. Hochedlinger.

In a separate paper, Dr. Jaenisch's group reports on their success in deriving human secondary iPS cells using doxycycline-inducible transgenes. "The drug-inducible system we describe represents a novel, predictable, and highly reproducible platform to study the kinetics of iPS cell generation," says Dr. Jaenisch. "Further, the genetic homogeneity of secondary cells makes chemical and genetic screening approaches to enhance reprogramming efficiency or to replace any of the original reprogramming factors feasible."

Both research teams found that generation of secondary human iPS cells required less time than the initial reprogramming. Interestingly, the time required to generate iPS cells varied among the types of skin cells that were used. For instance, human fibroblasts required several weeks, while keratinocytes required only about 10 days. "The fast kinetics of reprogramming observed for keratinocytes suggests that these cells would be useful for development and optimization of methods to reprogram cells by transient delivery of factors," suggests Dr. Hochedlinger.

The combined results from both research groups represent a major advance toward more efficient strategies for reprogramming differentiated human cells into iPS cells. The methods described here will not only provide critical insight into the reprogramming process, but also, because of the abbreviated time frame, may lead to the generation of cells that will be amenable for therapies, as reprogramming might be achievable without the prohibitive viruses or genetic modifications.

Source: Cell Press

Related stories:

What's good for the mouse is good for the monkey: Skin cells reprogrammed into stem cells
Scientists have successfully created the first induced pluripotent stem (iPS) cell lines from adult monkey skin cells. The research, published by Cell Press in the December issue of the journal Cell Stem Cell, demonstrates that the method of direct reprogramming is conserved among species and may be useful for creation of clinically valuable primate models for human diseases.
Researchers successfully reprogram keratinocytes attached to a single hair
The first reports of the successful reprogramming of adult human cells back into so-called induced pluripotent stem (iPS) cells, which by all appearances looked and acted liked embryonic stem cells created a media stir. But the process was woefully inefficient: Only one out of 10,000 cells could be persuaded to turn back the clock.
A breakthrough, then a surge, in stem cell research
Less than a year after a Wisconsin team helped discover a major alternative to human embryonic stem cells, the Madison scientists say more than 800 labs have begun using the approach, suggesting that many stem-cell researchers are starting to move beyond controversial embryonic sources for their work.
Researcher eliminates viral vector in stem cell reprogramming
Shinya Yamanaka MD, PhD, of Kyoto University and the Gladstone Institute of Cardiovascular Disease (GICD) has taken another step forward in improving the possibilities for the practical application of induced pluripotent stem (iPS) cell technology.
Important new step toward producing stem cells for human treatment
(PhysOrg.com) -- A team of Harvard Stem Cell Institute (HSCI) scientists has taken an important step toward producing induced pluripotent stem (iPS) cells that are safe to transplant into patients to treat diseases.
Researchers turn one form of adult mouse cell directly into another
(PhysOrg.com) -- In a feat of biological prestidigitation likely to turn the field of regenerative medicine on its head, Harvard Stem Cell Institute (HSCI) co-director Doug Melton and post doctoral fellow Qiao "Joe" Zhou report having achieved what has long been a dream and ultimate goal of developmental biologists – directly turning one type of fully formed adult cell into another type of adult cell.
Scientists create 20 disease-specific stem cell lines
(PhysOrg.com) -- Harvard Stem Cell Institute researcher George Q. Daley, associate director of the Stem Cell Program at Children's Hospital Boston, has with HSCI colleagues Chad Cowan and Konrad Hochedlinger of Massachusetts General Hospital produced a robust new collection of disease-specific stem cell lines, all of which were developed using the new induced pluripotent stem cell (iPS) technique. The work is described in a paper published in today's online edition of the journal Cell.
Recipe for cell reprogramming adds protein
A drug-like molecule called Wnt can be substituted for the cancer gene c-Myc, one of four genes added to adult cells to reprogram them to an embryonic-stem-cell-like state, according to Whitehead researchers. Researchers hope that such embryonic stem-cell-like cells, known as induced pluripotent (IPS) cells, eventually may treat diseases such as Parkinson's disease and diabetes.

News discussion:

General Science news